$5.59 Billion is the total value of ARMISTICE CAPITAL, LLC's 116 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMZN | AMAZON COM INC | $86,004,000 | +11.2% | 25,000 | 0.0% | 1.54% | -13.3% | |
| CPRX | CATALYST PHARMACEUTICALS INC | $57,500,000 | +24.7% | 10,000,000 | 0.0% | 1.03% | -2.7% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $20,360,000 | +10.0% | 3,856,000 | 0.0% | 0.36% | -14.4% | |
| CL | COLGATE PALMOLIVE CO | $19,199,000 | +3.2% | 236,000 | 0.0% | 0.34% | -19.4% | |
| VYGR | VOYAGER THERAPEUTICS INC | $15,347,000 | -12.3% | 3,716,000 | 0.0% | 0.28% | -31.6% | |
| EYEG | EYEGATE PHARMACEUTICALS INC | $12,182,000 | -26.9% | 3,346,601 | 0.0% | 0.22% | -43.1% | |
| AYTU | AYTU BIOPHARMA INC | $6,725,000 | -34.1% | 1,342,378 | 0.0% | 0.12% | -48.7% | |
| TENAX THERAPEUTICS INC | $4,201,000 | +9.5% | 2,019,995 | 0.0% | 0.08% | -14.8% | ||
| NERV | MINERVA NEUROSCIENCES INC | $2,116,000 | -20.5% | 912,000 | 0.0% | 0.04% | -37.7% | |
| LEXXW | LEXARIA BIOSCIENCE CORP*w exp 01/11/202 | $908,000 | +5.0% | 361,905 | 0.0% | 0.02% | -20.0% | |
| MDGSW | MEDIGUS LTD*w exp 07/23/202 | $720,000 | -34.9% | 1,285,715 | 0.0% | 0.01% | -48.0% | |
| SYTAW | SIYATA MOBILE INC*w exp 09/24/202 | $696,000 | -7.8% | 150,000 | 0.0% | 0.01% | -29.4% | |
| GROYWS | GOLD ROYALTY CORP*w exp 99/99/999 | $470,000 | 0.0% | 448,000 | 0.0% | 0.01% | -27.3% | |
| NLSPW | NLS PHARMACEUTICS LTD*w exp 09/25/202 | $452,000 | -4.8% | 500,000 | 0.0% | 0.01% | -27.3% | |
| AZRX | AZURRX BIOPHARMA INC | $49,000 | -38.8% | 59,863 | 0.0% | 0.00% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | 30 | Q3 2023 | 2.7% |
| SPDR S&P 500 ETF TR | 28 | Q3 2023 | 29.5% |
| MADRIGAL PHARMACEUTICALS INC | 27 | Q3 2023 | 2.9% |
| VANDA PHARMACEUTICALS INC | 26 | Q3 2021 | 9.4% |
| REGENERON PHARMACEUTICALS | 25 | Q3 2023 | 3.2% |
| ENERGIZER HLDGS INC NEW | 22 | Q2 2023 | 3.7% |
| ANTARES PHARMA INC | 21 | Q3 2020 | 6.6% |
| INCYTE CORP | 21 | Q3 2023 | 2.8% |
| VOYAGER THERAPEUTICS INC | 21 | Q3 2023 | 2.0% |
| BLUEBIRD BIO INC | 20 | Q4 2021 | 1.8% |
View ARMISTICE CAPITAL, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Avalo Therapeutics, Inc. | June 28, 2023 | 588,850 | 4.7% |
| Addex Therapeutics Ltd. | February 16, 2023 | 675,295 | 5.0% |
| Arcadia Biosciences, Inc. | February 14, 2023 | 2,675,409 | 10.0% |
| Avinger Inc | February 14, 2023 | 789,400 | 10.0% |
| Baudax Bio, Inc. | February 14, 2023 | 1,165,709 | 5.0% |
| BIORA THERAPEUTICS, INC. | February 14, 2023 | 12,989,648 | 5.7% |
| Bit Digital, Inc | February 14, 2023 | 3,161,889 | 3.7% |
| Bruush Oral Care Inc. | February 14, 2023 | 1,122,922 | 10.0% |
| CATALYST PHARMACEUTICALS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Clarus Therapeutics Holdings, Inc. | February 14, 2023 | 2,732,169 | 5.0% |
View ARMISTICE CAPITAL, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View ARMISTICE CAPITAL, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.